Resveratrol increases AdipoR1 and AdipoR2 expression in type 2 diabetic nephropathy. Issue 1 (December 2016)
- Record Type:
- Journal Article
- Title:
- Resveratrol increases AdipoR1 and AdipoR2 expression in type 2 diabetic nephropathy. Issue 1 (December 2016)
- Main Title:
- Resveratrol increases AdipoR1 and AdipoR2 expression in type 2 diabetic nephropathy
- Authors:
- Park, Hoon
Lim, Ji
Kim, Min
Kim, Yaeni
Hong, You
Choi, Sun
Chung, Sungjin
Kim, Hyung
Choi, Bum
Kim, Yong
Chang, Yoon
Park, Cheol - Abstract:
- Abstract Background Adiponectin has multiple functions including insulin sensitization, anti-inflammation and antiatherogenesis in various organs. Adiponectin activates 5′-adenosine monophosphate-activated protein kinase (AMPK) and peroxisome proliferator-activated receptor (PPAR)α via the adiponectin receptor (AdipoR) 1 and 2, which are critical for regulating lipids and glucose homeostasis and for controlling oxidative stress. We investigated whether resveratrol can inhibit renal damage in type 2 diabeticdb/db mice and the underlying mechanisms of its effects. Methods Four groups of male C57 BLKS/Jdb/m anddb/db mice and human glomerular endothelial cells (HGECs) were used. Resveratrol was administered to diabetic and nondiabetic mice by oral gavage for 12 weeks starting at 8 weeks of age. Results Indb/db mice, resveratrol increased serum adiponectin levels and decreased albuminuria, glomerular matrix expansion, inflammation and apoptosis in the glomerulus. Resveratrol increased the phosphorylation of AMPK and silent information regulator T1 (SIRT1), and decreased phosphorylation of downstream effectors class O forkhead box (FoxO)1 and FoxO3a via increasing AdipoR1 and AdipoR2 in the renal cortex. Furthermore, resveratrol increased expression of PPARγ coactivator (PGC)-1α, estrogen-related receptor-1α, and phosphorylated acetyl-CoA carboxylase and decreased sterol regulatory element-binding protein 1. This effect lowered the content of nonesterified fatty acid andAbstract Background Adiponectin has multiple functions including insulin sensitization, anti-inflammation and antiatherogenesis in various organs. Adiponectin activates 5′-adenosine monophosphate-activated protein kinase (AMPK) and peroxisome proliferator-activated receptor (PPAR)α via the adiponectin receptor (AdipoR) 1 and 2, which are critical for regulating lipids and glucose homeostasis and for controlling oxidative stress. We investigated whether resveratrol can inhibit renal damage in type 2 diabeticdb/db mice and the underlying mechanisms of its effects. Methods Four groups of male C57 BLKS/Jdb/m anddb/db mice and human glomerular endothelial cells (HGECs) were used. Resveratrol was administered to diabetic and nondiabetic mice by oral gavage for 12 weeks starting at 8 weeks of age. Results Indb/db mice, resveratrol increased serum adiponectin levels and decreased albuminuria, glomerular matrix expansion, inflammation and apoptosis in the glomerulus. Resveratrol increased the phosphorylation of AMPK and silent information regulator T1 (SIRT1), and decreased phosphorylation of downstream effectors class O forkhead box (FoxO)1 and FoxO3a via increasing AdipoR1 and AdipoR2 in the renal cortex. Furthermore, resveratrol increased expression of PPARγ coactivator (PGC)-1α, estrogen-related receptor-1α, and phosphorylated acetyl-CoA carboxylase and decreased sterol regulatory element-binding protein 1. This effect lowered the content of nonesterified fatty acid and triacylglycerol in the kidneys, decreasing apoptosis, oxidative stress and activating endothelial nitric oxide synthase. Resveratrol prevented cultured HGECs from undergoing high-glucose-induced oxidative stress and apoptosis by activating the AMPK–SIRT1–PGC–1α axis and PPARα through increases in AdipoR1 and AdipoR2 expression. Conclusions These results suggest that resveratrol prevents diabetic nephropathy by ameliorating lipotoxicity, oxidative stress, apoptosis and endothelial dysfunction via increasing AdipoR1 and AdipoR2 expression. … (more)
- Is Part Of:
- Journal of translational medicine. Volume 14:Issue 1(2016)
- Journal:
- Journal of translational medicine
- Issue:
- Volume 14:Issue 1(2016)
- Issue Display:
- Volume 14, Issue 1 (2016)
- Year:
- 2016
- Volume:
- 14
- Issue:
- 1
- Issue Sort Value:
- 2016-0014-0001-0000
- Page Start:
- 1
- Page End:
- 13
- Publication Date:
- 2016-12
- Subjects:
- Adiponectin -- 5′-adenosine monophosphate-activated protein kinase -- Diabetic nephropathy -- Resveratrol
Medicine, Experimental -- Periodicals
Human experimentation in medicine -- Periodicals
Therapeutics -- Periodicals
615.50724 - Journal URLs:
- http://www.pubmedcentral.gov/tocrender.fcgi?journal=214 ↗
http://www.translational-medicine.com/home/ ↗
http://link.springer.com/ ↗ - DOI:
- 10.1186/s12967-016-0922-9 ↗
- Languages:
- English
- ISSNs:
- 1479-5876
- Deposit Type:
- Legaldeposit
- View Content:
- Available online (eLD content is only available in our Reading Rooms) ↗
- Physical Locations:
- British Library DSC - BLDSS-3PM
British Library HMNTS - ELD Digital store - Ingest File:
- 9897.xml